Aboriginal and Torres Strait Islander people: Adult immunisations
Aboriginal and Torres Strait Islander peoples have higher rates of some vaccine preventable diseases. Some National Immunisation Program vaccines can be accessed at a younger age for people in this population group. The below table summarises the vaccines recommended for Aboriginal and Torres Strait Islander peoples by adult age groups:
Aboriginal people 70-79 years
Zoster (shingles) vaccineZostavax®
Funded for all 70-year-oldsFunded catch up extended until 31/10/2023 for all 71-79 year olds
Aboriginal people ≥50 years
Pneumococcal vaccinePrevenar 13®: from 50 yearsPneumovax 23®: 2-12 months laterPneumovax 23®: at least 5 years later
Aboriginal and Torres Strait Islander people: COVID-19 vaccination uptake
The COVID-19 vaccination report (27 April 2022) lists the percentage of people who have self-identified as Indigenous who have been vaccinated against COVID-19 by local government area (LGA). The percentages are broken down for individuals who have received 2 doses, and individuals who have received 3 or more doses. *It should be noted when interpreting the data, that COVID-19 vaccination is now recommended to be delayed by 3 months after a confirmed SARS-CoV-2 infection which may affect uptake.
mRNA vaccine dose interval: extended to 8 weeks
ATAGI recommends an 8-week interval between dose one and dose two for Pfizer and Moderna for people aged 5 years and older, particularly for males aged 12 to 39 years. The extended dose interval has been shown to improve the immune response to vaccination, may improve effectiveness, and may also reduce the risk of myocarditis and pericarditis.
The dose interval can be reduced (to a minimum of 3 weeks for Pfizer or 4 weeks for Moderna) for people at higher risk of severe COVID-19 (including older adults and people with underlying medical conditions), in an outbreak setting, or prior to international travel.
ATAGI flowchart: COVID-19 vaccine recommendation by age and population group
This flowchart (updated 2 May 2022) summarises the ATAGI recommendations relating to COVID-19 vaccines. It outlines the appropriate vaccine brand and doses that are recommended for each age and population group.
Defer COVID-19 vaccination for 3 months after SARS-CoV-2 infection
Vaccination is recommended to be deferred for at least 3 months after a confirmed SARS-CoV-2 infection for all COVID-19 vaccine doses, including booster doses. This updated advice reflects the lower risk of reinfection with the Omicron variant within the first 3 months following a confirmed infection, particularly if prior COVID-19 vaccine doses have been received.
This recommendation does not apply to other vaccines (for example, influenza vaccinations) which can continue to be administered as soon as a person recovers from acute infection.
RAT now acceptable for temporary vaccine exemption
Rapid antigen tests reported to the State reporting system are now considered acceptable proof of infection for the purposes of a temporary medical exemption to delay vaccination. The time frame for temporary deferral of vaccination following SARS-CoV-2 infection has been updated from 6 months to 4 months.
IFNAR1 Deficiency and serious adverse events following immunisation
IFNAR1 deficiency is a rare inherited condition affecting some people in Australia of Western Polynesian heritage including Tongan, Samoan, and Niuean people. The Chief Medical Officer has provided ATAGI information
On 27 April 2022 the TGA granted provisional determination for the Moderna bivalent COVID-19 vaccine “Spikevax Bivalent Zero/Omicron”. Moderna has developed a bivalent vaccine that includes the mRNA sequence encoding the spike protein of the Omicron variant of concern and the original Spikevax vaccine.
Provisional determination means that Moderna is now able to apply for provisional registration for the bivalent vaccine for active immunisation to prevent COVID-19, but does not guarantee approval of the application.
COVID-19 live stream update for GPs
COVID-19 vaccine live stream for GPs – key updates and live Q&A
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…